The Fred Hutch Postbaccalaureate Scholar Program provides recent college graduates $50,000 a year and benefits as full-time Fred Hutch employees with an expanded emphasis on career guidance and preparation for further studies.
The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.
The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.
Therapy for chronic myelomonocytic leukemia (CMML) has made little progress during the last 15 years, mainly because standard therapies have been adopted f
PHILADELPHIA (November 11, 2024) — Disha Sawhney, FACHDM, FRSPH, Manager of Service Line Operations at Fox Chase Cancer Center, was recently awarded a 2024 Future…
Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.
Lactylation, a recently identified post-translational modification, has initially been linked to gene transcription regulation through epigenetic mechanisms. However, its role in tumorigenesis—whether as a major…
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed…
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
An abstract is unavailable.
Five-fraction SBRT was noninferior to radiotherapy in a phase 3 trial of patients with low- to intermediate-risk localized prostate cancer.
